Loading…
This entity appears on both sides of lobbying disclosures. The firm tab shows registrant-reported income; the client tab shows client-reported lobbying spend. Contract awards are separate and are not included here.
Lobbying Spend
$60K
Filings
8
Firms Hired
2
Active Period
2021–2022
Client-reported lobbying expenses on LDA filings
Lobbying firms retained by this client; amounts are client-reported expenses when available
Government entities explicitly identified as targets in LDA filings
Most frequently reported lobbying issues
Bill numbers found in source-reported LDA specific issue text; broad topic matches are excluded
Inflation Reduction Act of 2022
2022 · first_quarter · Firm: SPLITOAK STRATEGIES LLC
HR 5376, Build Back Better Act-impact on rare disease research
Client expense: — · Firm income: $30,000
Matched citations: HR 5376
Inflation Reduction Act of 2022
2022 · first_quarter · Firm: SPLITOAK STRATEGIES LLC
HR 5376, Build Back Better Act-impact on rare disease research
Client expense: — · Firm income: $30,000
Matched citations: HR 5376
Inflation Reduction Act of 2022
2022 · first_quarter · Firm: SPLITOAK STRATEGIES LLC
HR 5376, Build Back Better Act-importance of the Orphan Drug Tax Credit for rare diseases
Client expense: — · Firm income: $30,000
Matched citations: HR 5376
Inflation Reduction Act of 2022
2021 · fourth_quarter · Firm: SPLITOAK STRATEGIES LLC
HR 5376, Build Back Better Act-impact on rare disease research
Client expense: — · Firm income: $30,000
Matched citations: HR 5376
Inflation Reduction Act of 2022
2021 · fourth_quarter · Firm: SPLITOAK STRATEGIES LLC
HR 5376, Build Back Better Act-importance of the Orphan Drug Tax Credit for rare diseases
Client expense: — · Firm income: $30,000
Matched citations: HR 5376
Inflation Reduction Act of 2022
2021 · fourth_quarter · Firm: SPLITOAK STRATEGIES LLC
HR 5376, Build Back Better Act-impact on rare disease research
Client expense: — · Firm income: $30,000
Matched citations: HR 5376
Elijah E. Cummings Lower Drug Costs Now Act
2021 · fourth_quarter · Firm: ACCELERON PHARMA INC
The client is engaging on H.R. 3 - Lower Drug Costs Now Act and prescription drug pricing legislation generally.
Client expense: $20,000 · Firm income: —
Matched citations: H.R. 3
Elijah E. Cummings Lower Drug Costs Now Act
2021 · third_quarter · Firm: SPLITOAK STRATEGIES LLC
HR 3, impact on rare disease research
Client expense: — · Firm income: $30,000
Matched citations: HR 3
Elijah E. Cummings Lower Drug Costs Now Act
2021 · third_quarter · Firm: SPLITOAK STRATEGIES LLC
HR 3, Impact on rare disease research
Client expense: — · Firm income: $30,000
Matched citations: HR 3
Elijah E. Cummings Lower Drug Costs Now Act
2021 · third_quarter · Firm: ACCELERON PHARMA INC
The client is engaging on H.R. 3 - Lower Drug Costs Now Act and prescription drug pricing legislation generally.
Client expense: $20,000 · Firm income: —
Matched citations: H.R. 3
Elijah E. Cummings Lower Drug Costs Now Act
2021 · third_quarter · Firm: SPLITOAK STRATEGIES LLC
Rare disease patient access to needed therapies (HR 3), Value of Medicare Parts B and D
Client expense: — · Firm income: —
Matched citations: HR 3
Elijah E. Cummings Lower Drug Costs Now Act
2021 · second_quarter · Firm: ACCELERON PHARMA INC
The client is engaging on H.R. 3 - Lower Drug Costs Now Act and prescription drug pricing legislation generally.
Client expense: $20,000 · Firm income: —
Matched citations: H.R. 3
Patient access to innovative biopharmaceuticals, pricing and reimbursement of medicines (HR 3), barriers to patient access via utilization management tools such as step therapy (HR 2163), FDA issues such as Accelerated Approval program.
Client expense: — · Firm income: —
Matched citations: HR 2163
Elijah E. Cummings Lower Drug Costs Now Act
2021 · second_quarter · Firm: ACCELERON PHARMA INC
Patient access to innovative biopharmaceuticals, pricing and reimbursement of medicines (HR 3), barriers to patient access via utilization management tools such as step therapy (HR 2163), FDA issues such as Accelerated Approval program.
Client expense: — · Firm income: —
Matched citations: HR 3
Source: Senate LDA